NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Chemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents

RecruitingPhase 2, Phase 3

Sponsor: Children's Cancer Group, China

Conditions: Mature B-cell Non-Hodgkin Lymphoma

Interventions: Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Drug: Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone

Countries: China

The purpose of this study is to test whether intensive chemotherapy combined with early, adequate, and intensive use of Rituximab for aggressive B-NHL in children and adolescents can improve the EFS and OS compared with the historical study CCCG-BNHL-2015.

Eligibility overview

Sex: ALL

Age: — to 18 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histology or cytologically confirmed mature B-cell NHL/AL(Burkitt, DLBCL, PMLBL,or aggressive mature B-cell NHL non other specified or specifiable)
* Able to comply with scheduled follow-up and with management of toxicity
* Signed informed consent

Exclusion Criteria:

* Follicular lymphoma, MALT and nodular marginal zone are not included into this therapeutic study
* Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology.
* Evidence of pregnancy or lactation period. Past or current anti-cancer treatment except corticosteroids during less than one week.

Exclusion Criteria related to Rituximab :

* Tumor cell negative for CD20
* Prior exposure to rituximab
* Hepatitis B carrier status history of HBV or positive serology.

Locations (1)

Shanghai, Shanghai Municipality, China